Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Cecilia M Shikuma, M.D.
University of Hawaii - Hawaii Center for AIDS (HICFA)
Principal Investigator - Thuy Le, M.D.
University of Hawaii, Oxford University Clinical Research Unit
Study Director - Van Vinh Chau Nguyen, MD, PhD
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Viet Tiep General Hospital
Haiphong, Vietnam
- Hospital for Tropical Diseases
Ho Chi Minh City, Vietnam
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2014
- Primary completion
- 1 Jun 2016
- Completion
- 1 Jun 2021
- Last update posted
- 13 Aug 2021
- Registered enrollment
- 80
- Registry id
- NCT01147107
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.